FotoFacial RF® for Color Correction - Highly sensitive light energies are absorbed by hemoglobin and pigmented lesions to treat freckles, age spots, and sun damage to any part of the body. The result is a smooth, luminous, more youthful appearance.

ReFirme® - This is an excellent non-surgical skin tightening procedure for sagging and wrinkled skin, jowl and neck laxity, saggy brow lines, and naso-labial folds. Bi-polar radiofrequency heat and infrared laser light heat the dermal tissue, stimulate collagen production, and produce a firming effect. Noticeable lifting can be observed as skin texture becomes more smooth and elastic.

Matrix IR® - This laser treatment combines fractional optical energy with bi-polar radio frequency to create thermal bands deep in the dermis effectively treating mild to moderate wrinkles. The Matrix IR stimulates collagen formation deep within the dermis layer while protecting the epidermis. The result is decreased wrinkles and renewed skin.

Triniti® Total Facial Renewal - This complete skin program combines FotoFacial RF, ReFirme, and MatrixIR during the same session for immediate, visible, and long-lasting results. Triniti achieves color correction, improved skin texture and laxity, and wrinkle reduction. For optimal results, a series of 3 treatments are performed every 3 to 4 weeks.

Matrix RF® - A bi-polar radio-frequency skin treatment for skin laxity, scars, acne scars, textural irregularities, tone, and superficial skin lesions. The treatment generates fractional deep dermal heating bands to induce skin injury, thus inducing a wound healing response of the tissue surrounding the matrix points leading to tighter, rejuvenated appearance of the skin. The newly FDA-cleared Matrix RF is the only fractional resurfacing device utilizing this form of fractional energy delivery, greatly enhancing both safety and patient outcomes for skin of all colors. Most patients showed improvement in facial parameters such as skin brightness (83%) and skin smoothness/ wrinkle reduction (90%)1. 1 Journal of Drugs & Dermatology, March 2009.